These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 21683865)

  • 1. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
    Kurman RJ; Shih IeM
    Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
    Kurman RJ; Shih IeM
    Am J Surg Pathol; 2010 Mar; 34(3):433-43. PubMed ID: 20154587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
    Kurman RJ
    Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
    Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2008 Apr; 27(2):151-60. PubMed ID: 18317228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precursors and pathogenesis of ovarian carcinoma.
    Lim D; Oliva E
    Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 9. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
    Kurman RJ; Visvanathan K; Roden R; Wu TC; Shih IeM
    Am J Obstet Gynecol; 2008 Apr; 198(4):351-6. PubMed ID: 18395030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
    Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
    Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origins and molecular pathology of ovarian cancer.
    Bell DA
    Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology of epithelial ovarian cancer.
    Christie M; Oehler MK
    J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
    Shih IeM; Kurman RJ
    Am J Pathol; 2004 May; 164(5):1511-8. PubMed ID: 15111296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
    Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N
    Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent concepts of ovarian carcinogenesis: type I and type II.
    Koshiyama M; Matsumura N; Konishi I
    Biomed Res Int; 2014; 2014():934261. PubMed ID: 24868556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.
    Kurman RJ; Shih IeM
    Am J Pathol; 2016 Apr; 186(4):733-47. PubMed ID: 27012190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The dualistic model and extraovarian origin theory of ovarian epithelial cancer].
    Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2013 Apr; 48(4):310-3. PubMed ID: 23902820
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.